Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Narrative)

v3.22.1
Commitments and Contingencies (Details Narrative) - USD ($)
2 Months Ended 3 Months Ended
Apr. 09, 2021
Aug. 12, 2020
Sep. 12, 2018
Aug. 20, 2018
Mar. 22, 2018
Sep. 14, 2015
Dec. 24, 2013
Aug. 31, 2020
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Loss Contingencies [Line Items]                      
Contractual commitment                 $ 8,399,000    
Research and development costs                 458,450 $ 443,526  
City of Hope [Member]                      
Loss Contingencies [Line Items]                      
Aggregate commitments expected                 307,000    
GEIS [Member]                      
Loss Contingencies [Line Items]                      
Amount related to milestone payment                 67,582    
NDA Consulting Corp [Member]                      
Loss Contingencies [Line Items]                      
Consulting and advisory fee             $ 4,000   4,000 4,000  
Clinical Trial Research Agreement [Member]                      
Loss Contingencies [Line Items]                      
Advance amount related to milestone payment                 3,332 7,384  
Research and development costs                 $ 108,009    
Aggregate commitments expected, description                 The Company’s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $600,000 as of March 31, 2022, which is expected to be incurred through December 31, 2025    
Aggregate commitments expected                 $ 600,000    
Collaboration Agreement [Member] | GEIS [Member]                      
Loss Contingencies [Line Items]                      
Advance amount related to milestone payment                 0 24,171  
Research and development costs                 $ 155,053    
Aggregate commitments expected, description                 The Company’s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $4,166,000 as of March 31, 2022, which is expected to be incurred through December 31, 2025    
Aggregate commitments expected                 $ 4,166,000    
Collaboration Agreement [Member] | BioPharmaWorks LLC [Member]                      
Loss Contingencies [Line Items]                      
Consulting and advisory fee           $ 10,000          
Reimbursed expense                 30,000 30,000  
Development Agreement [Member]                      
Loss Contingencies [Line Items]                      
Research and development costs                 $ 292,293    
Aggregate commitments expected, description                 The Company’s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $29,000 as of March 31, 2022, which is expected to be incurred through June 30, 2022    
Aggregate commitments expected                 $ 29,000    
Other Clinical Agreements [Member]                      
Loss Contingencies [Line Items]                      
Research and development costs                 1,153,000    
Aggregate commitments expected                 206,000    
Clinical Research Support Agreement [Member]                      
Loss Contingencies [Line Items]                      
Aggregate commitments expected                 800,000    
Clinical Research Support Agreement [Member] | City of Hope [Member]                      
Loss Contingencies [Line Items]                      
Research and development costs                 0 240,508  
Aggregate commitments expected                 2,433,000    
Work Order Agreement [Member]                      
Loss Contingencies [Line Items]                      
Research and development costs                 95,166    
Aggregate commitments expected                 864,000    
Work Order Agreement [Member] | City of Hope [Member]                      
Loss Contingencies [Line Items]                      
Advance amount related to milestone payment                 4,500 3,540  
Aggregate commitments expected                 29,126    
Work Order Agreement [Member] | Theradex Systems, Inc. [Member]                      
Loss Contingencies [Line Items]                      
Research and development costs     $ 954,000           3,281 941  
Material Transfer Agreement [Member] | INSERM [Member]                      
Loss Contingencies [Line Items]                      
Aggregate commitments expected                 0   $ 0
Material Transfer Agreement [Member] | INSERM [Member] | Development Milestones [Member] | Maximum [Member]                      
Loss Contingencies [Line Items]                      
Milestone payments         $ 1,750,000            
Material Transfer Agreement [Member] | INSERM [Member] | Commercial Milestones [Member] | Maximum [Member]                      
Loss Contingencies [Line Items]                      
Milestone payments         $ 6,500,000            
Exclusive License Agreement [Member] | First Four Years [Member]                      
Loss Contingencies [Line Items]                      
Minimum payments for royalties                 50,000    
Exclusive License Agreement [Member] | Five Years And Thereafter [Member]                      
Loss Contingencies [Line Items]                      
Minimum payments for royalties                 100,000    
Exclusive License Agreement [Member] | Moffitt Cancer Center and Research Institute Hospital Inc [Member]                      
Loss Contingencies [Line Items]                      
Non-refundable license issue fee       $ 25,000              
Annual license maintenance fee       25,000              
Payments on non-refundable milestone       $ 1,897,000              
Amount charges to operations                 6,165 $ 6,164  
Employment Agreement [Member] | Executive Officers [Member]                      
Loss Contingencies [Line Items]                      
Salary and Wage, Excluding Cost of Good and Service Sold               $ 640,000      
Agreement term description               one-year period      
Employment Agreement [Member] | Dr.James [Member]                      
Loss Contingencies [Line Items]                      
Annual compensation $ 775,000                    
Master Service Agreement [Member] | Foundation for Angelman Syndrome Therapy [Member]                      
Loss Contingencies [Line Items]                      
Percentage of proceeds agree to pay under agreement   5.00%                  
Maximum amount received under agreement   $ 250,000                  
Development Collaboration Agreement [Member] | Netherlands Cancer Institute [Member]                      
Loss Contingencies [Line Items]                      
Advance amount related to milestone payment                 54,230    
Research and development costs                 $ 109,478    
Aggregate commitments expected, description                 The Company’s aggregate commitment pursuant to this collaboration agreement, less amounts previously paid to date, totaled approximately $380,000 as of March 31, 2022, which is expected to be incurred through June 30, 2025    
Aggregate commitments expected                 $ 380,000